DVA

Business Context and Reporting Period

Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended September 30, 2003
Business Overview: DaVita operates dialysis centers and laboratories, providing services primarily to patients with end-stage renal disease. The company generates revenue through Medicare, Medicaid, and private payors.

Key Financial Metrics

Operational Metrics (Q3 2003):

• Dialysis treatments: 1,625,058
• Average revenue per treatment: $306.20
• Operating margin: 18.5% (excluding prior period lab recoveries)

Material Changes vs. Prior Period

• Revenue Growth: Q3 2003 revenue increased 6.7% year-over-year. Excluding a one-time $27 million lab recovery in Q3 2002, organic growth was approximately 13%, driven by a 7% increase in treatment volume and a 5% increase in average reimbursement rates.
• Profitability Decline: Net earnings for Q3 2003 dropped 29.7% compared to Q3 2002. This decline is primarily attributed to the absence of the $27 million prior-period laboratory revenue recognized in Q3 2002 and increased operating expenses.
• Debt Restructuring: The company significantly reduced its debt burden and interest rates. In July 2003, it redeemed $125 million of 5 5/8% convertible notes (mostly converted to equity) and refinanced its Term Loan B to lower the effective interest rate to 3.64%. In August 2003, it redeemed $200 million of 7% convertible notes.
• Refinancing Charges: The company incurred $17.2 million in refinancing charges in Q3 2003 related to debt redemptions and write-offs of deferred financing costs.
• Share Repurchases: The company repurchased 2.74 million shares for $83 million in Q3 2003, reducing the share count and increasing earnings per share relative to net income.

Guidance, Outlook, and Risks

Outlook:

• Q4 2003: Management expects operating income to be comparable to Q3 2003.
• 2004 Target: Operating income is targeted between $360 million and $385 million.

Management Commentary:

• Revenue growth is driven by commercial pricing, payor mix, and billing improvements.
• Operating expenses increased due to higher insurance, labor, and pharmaceutical costs.
• Debt expense decreased significantly due to lower average interest rates (4.3% in Q3 2003 vs. 5.9% in Q3 2002).

Risks and Contingencies:

• Regulatory Investigations: Ongoing reviews by the U.S. Attorney's Office, OIG, and DOJ regarding historical billing practices and financial relationships with physicians. A third-party carrier review of the Florida laboratory remains unresolved, with approximately $31.5 million in claims still in dispute for prior periods.
• Reimbursement Rates: Significant exposure to declines in private payor rates and potential changes to the Medicare ESRD composite rate, which could negatively impact revenue if ancillary services (like EPO) are bundled without adequate rate increases.
• IT Implementation: Rollout of new information technology systems may disrupt billing and collection activities.
• Medical Director Relationships: Risk of losing patient referrals if medical director agreements are not renewed or are terminated.

Investor Verification Checklist

• Debt Status: Verify the completion of the redemption of the remaining $145 million of 7% convertible notes (completed Oct 14, 2003) and the impact on future interest expense.
• Lab Dispute Resolution: Monitor the status of the Florida laboratory Medicare carrier review and the potential for further revenue adjustments or penalties.
• Regulatory Outcomes: Track developments in the U.S. Attorney's Office and OIG investigations regarding billing practices and physician relationships.
• Reimbursement Trends: Assess the stability of private payor reimbursement rates and any legislative changes to Medicare ESRD payment structures.
• IT System Rollout: Evaluate the impact of new billing systems on days sales outstanding (DSO) and cash flow collection efficiency.